Selvedge Venture

Mesh Bio is a digital health startup focused on enhancing chronic disease management through its multidimensional health intelligence platform. The company collaborates with healthcare providers and stakeholders to deliver innovative solutions that improve health screening and disease management. By automating health screening report generation and increasing accuracy, Mesh Bio's platform translates clinical data into actionable insights. This enables patients to better manage their health, lifestyle, and disease risks while providing healthcare providers with a holistic assessment of patient conditions.

BIOS Health is a pioneering company focused on developing neural digital therapies by harnessing data-driven insights from the human nervous system. Co-founded by researchers from Cambridge University, the firm aims to revolutionize precision medicine through the identification of neural biomarkers that link nerve activity to various medical conditions. BIOS's innovative approach holds promise for treating chronic diseases such as hypertension, diabetes, rheumatoid arthritis, and neurodegenerative disorders like Parkinson's and Alzheimer's. The company's expertise encompasses a diverse range of fields, including neuroscience, machine learning, software engineering, and biotechnology, allowing it to create advanced solutions for improving the quality of life for individuals suffering from these conditions. Additionally, BIOS is engaged in developing prosthetic connectors that standardize the interface between bionic devices and the body's nervous and soft-tissue systems, enabling enhanced control and feedback for patients with prosthetics.

Carbometrics is a specialist chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Founded by the team behind the successful development of a glucose-binding molecule platform, the company leverages over 20 years of research from Professor Anthony Davis’ group at the University of Bristol. Carbometrics aims to create a robust and accurate glucose sensing platform that will lead to an innovative Continuous Glucose Monitoring (CGM) solution, enabling individuals with diabetes to monitor their glucose levels more effectively. Following the sale of their previous venture, Ziylo, to Novo Nordisk, the founders are committed to developing advanced technologies to improve the management of diabetes and enhance patients' quality of life.

MultiOmic Health is a company focused on addressing metabolic syndrome-related diseases through AI-enabled drug discovery. It collaborates with healthcare providers to gather and analyze de-identified patient data and bio-samples. The company's MOHSAIC® platform integrates multi-omics analysis, computational systems biology modeling, and targeted laboratory experiments to develop novel precision therapeutic concepts. These concepts are then commercialized through partnerships with established biopharma companies.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

Oxford Medical Products is focused on developing a breakthrough gastro-retentive hydrogel technology aimed at addressing weight loss challenges. The company has created a self-expanding capsule that occupies space in the stomach, effectively reducing hunger and promoting significant weight loss. This innovative solution is designed to expand rapidly upon ingestion, providing a prolonged feeling of satiety. The capsules gradually break down and pass naturally through the digestive system, offering an affordable and safe option for individuals seeking to manage their weight. Led by a diverse team of scientists, medical professionals, and entrepreneurs, Oxford Medical Products is dedicated to tackling one of the most pressing medical issues in today's society.

MultiOmic Health is a company focused on addressing metabolic syndrome-related diseases through AI-enabled drug discovery. It collaborates with healthcare providers to gather and analyze de-identified patient data and bio-samples. The company's MOHSAIC® platform integrates multi-omics analysis, computational systems biology modeling, and targeted laboratory experiments to develop novel precision therapeutic concepts. These concepts are then commercialized through partnerships with established biopharma companies.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

Sanome is a healthcare technology company focused on enhancing clinical decision-making through early detection and prevention of health issues. The company is developing a Clinical Co-pilot that leverages a multimodal generative AI platform to analyze various healthcare data streams and generate actionable insights. By integrating artificial intelligence with biophysical biomarkers, including at-home composite tests, Sanome aims to identify potential health changes before they escalate into serious conditions. This innovative approach is designed to improve patient outcomes and streamline healthcare efficiency by providing clinicians with timely information that can inform their decisions. Ultimately, Sanome envisions creating a human digital twin that continuously monitors individual health, further supporting clinicians in delivering proactive care.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

Yuri is a company specializing in the design and manufacturing of hardware for the aviation and aerospace industry. It offers a comprehensive range of services aimed at supporting microgravity research and experiments. These services encompass mission definition, hardware selection and development, as well as launch and return logistics. In addition to its focus on space missions, Yuri is involved in various scientific research areas, including growing cell cultures in 3D, modeling human diseases, analyzing proteins and molecules, synthetic biology, studying plant biology, and nanofluidics. This diverse expertise positions Yuri as a key player in advancing research capabilities within the aerospace sector.

MultiOmic Health is a company focused on addressing metabolic syndrome-related diseases through AI-enabled drug discovery. It collaborates with healthcare providers to gather and analyze de-identified patient data and bio-samples. The company's MOHSAIC® platform integrates multi-omics analysis, computational systems biology modeling, and targeted laboratory experiments to develop novel precision therapeutic concepts. These concepts are then commercialized through partnerships with established biopharma companies.

Oxford Medical Products is focused on developing a breakthrough gastro-retentive hydrogel technology aimed at addressing weight loss challenges. The company has created a self-expanding capsule that occupies space in the stomach, effectively reducing hunger and promoting significant weight loss. This innovative solution is designed to expand rapidly upon ingestion, providing a prolonged feeling of satiety. The capsules gradually break down and pass naturally through the digestive system, offering an affordable and safe option for individuals seeking to manage their weight. Led by a diverse team of scientists, medical professionals, and entrepreneurs, Oxford Medical Products is dedicated to tackling one of the most pressing medical issues in today's society.

Avro Life Science is a Canadian company focused on developing transdermal drug delivery systems, specifically medicated skin patches designed for the pediatric and elderly populations. Utilizing a novel biopolymer as a platform, Avro's technology enables passive delivery of small molecules and drugs directly into the bloodstream, allowing for a slow-release mechanism. This innovative approach aims to enhance medication accessibility while minimizing the impact on the liver, ultimately improving health outcomes and quality of life for its patients.

Exogene is a biotechnology company focused on advancing T-cell receptor (TCR)-based cancer immunotherapies for solid tumors. By integrating deep learning with high-throughput TCR-antigen screening, Exogene aims to efficiently identify new tumor targets that are common among cancer patients. The company is developing a computational platform designed to discover effective and safe TCRs against these targets, facilitating their therapeutic application. This innovative approach allows for the rapid and cost-effective development of TCR-based immunotherapies, ultimately supporting healthcare providers in creating cell therapies that enhance the immune system's ability to combat cancer.

PharmaCCX is a healthcare technology company established in 2017, headquartered in Boston with additional offices in Stockholm, San Mateo, and Zug. It operates a platform that facilitates pricing negotiations and procurement processes between oncology pharmaceutical companies and healthcare payers, aiming to accelerate patient access to necessary medicines. The platform offers a configurable infrastructure for planning, negotiating, and managing deals, enabling market access teams at pharma companies and payers to efficiently administer innovative payment models.